**Appendix 4.** Medications that can be indicated for infertility treatment.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Medication Name** | **Generic Name** | **Pregnancy Categorya** | **Drug Type** | **Treatment Usageb** |
| Follistim | follitropin | X | Gonadotropin | Induce ovulation |
| Novarel | chorionic gonadotropin (Human) | X |
| Ovidrel | chorionic gonadotropin (recombinant) | X |
| Chorionic\_Gonadotropin | chorionic gonadotropin | X |
| Menopur | follicle stimulating hormone / luteinizing hormone | X |
| progesterone  Prometrium | progesterone | B | Progesterone | Luteal phase support, previous miscarriage |
| Medroxyprogesterone | medroxyprogesterone | X | Progestin | Oral contraceptive prior to the ARTc cycle |
| Clomiphene | clomiphene | X | Selective estrogen receptor modulator | Induce ovulation |
| Cabergoline | cabergoline | B | Dopamine receptor agonist | Hyperprolactinemia |
| Vivelle  Estrace  Estradiol | estradiol | X | Estrogen | Menopause symptoms, maturation of endometrial lining |
| Letrozole | letrozole | N | Aromatase inhibitor | Post-menopausal breast cancer (on-label), infertility for PCOS (off-label) |

a US FDA five letter risk categories (since 2015 replaced with PLLR labeling) to indicate the potential of a drug to cause birth defects if used during pregnancy: A (adequate evidence to support safety), B (no adequate studies in humans and animal reproduction studies have failed to demonstrate risk), C (animal reproduction studies show adverse effect, and no adequate studies in humans), D (positive evidence of adverse risk on the fetus in humans), X (contraindicated, studies in animals or humans well demonstrate birth defects risk), N (not formally assigned a category)

b Treatment usage reflects treatment indication in assisted reproductive technology. This includes off-label use of drugs approved for other indications. Accordingly, these medications may be used for other indications. [35]

cART: Assisted Reproductive Technology